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Terpinen-4-ol, a monoterpene component of the essential oils of several aromatic plants, exhibits antitumor eﬀects. In this study,
the antitumor eﬀects of terpinen-4-ol and the cellular and molecular mechanisms responsible for it were evaluated and studied,
respectively onhumannonsmallcell lung cancer(NSCLC)cells. Ourresults indicated thatterpinen-4-ol elicited a dose-dependent
cytotoxic eﬀect, as determined by MTT assay. Increased sub-G1 population and annexin-V binding, activation of caspases 9
and 3, cleavage of poly(ADPribose) polymerase (PARP), and a decrease of mitochondrial membrane potential (MMP) indicated
involvement of the mitochondrial apoptotic pathway in terpinen-4-ol-treated A549 and CL1-0 cells. Elevation of the Bax/Bcl-2
ratio and a decrease in IAP family proteins XIAP and survivin were also observed following terpinen-4-ol treatment. Notably,
terpinen-4-ol was able to increase p53 levels in A549 and CL1-0 cells. Diminution of p53 by RNA interference induced necrosis
instead of apoptosis in A549 cells following terpinen-4-ol treatment, indicating that terpinen-4-ol-elicited apoptosis is p53-
dependent. Moreover, intratumoral administration of terpinen-4-ol signiﬁcantly suppressed the growth of s.c. A549 xenografts
by inducing apoptosis, as conﬁrmed by TUNEL assay. Collectively, these data provide insight into the molecular mechanisms
underlying terpinen-4-ol-induced apoptosis in NSCLC cells, rendering this compound a potential anticancer drug for NSCLC.
1.Introduction
Lung cancer is the leading cause of cancer-related deaths
worldwide. Among lung cancers,n o n s m a l lc e l ll u n gc a r c i n o -
mas (NSCLC)accountfor approximately80% of lungcancer
cases [1]. Despite improvements in survival through early
detection and treatment, rapid disease recurrence and pro-
gression still plague some patients [2]. Thus, the search for
new therapeutic approaches is still important and urgently
needed in clinical oncology.
Monoterpenes are major plant-derived secondary met-
abolites; they consist of two isoprene units, are found in es-
sential oils, and are associated with plant defense [3, 4]. In
addition, numerous monoterpenes have been proposed to
exert potent antitumor action, and some have shown prom-
ising results in the prevention and treatment of a variety
of cancers in tumor model systems [5, 6]. Notably, two
naturally occurring monoterpenes, perillyl alcohol (POH)
and limonene (LIM), are currently undergoing clinical trials
to evaluate their therapeutic eﬀect [7, 8].
Terpinen-4-ol, anaturally occurring monoterpene found
in the essential oils of many aromatic plants including
Melaleuca alternifolia (tea tree oil), Hajeb Layoun arboreta
(Tunisia) and Alpinia zerumbet, has been shown to have
antiviral, antibacterial, antifungal, and insecticidal eﬀects as
well as antioxidant and anti-inﬂammatory activities [9–13].
Recent reports have indicated that terpinen-4-ol exerts its
antitumor eﬀects by triggering caspase-dependent apoptosis
in human melanoma cells or by inducing necrotic cell death2 Evidence-Based Complementary and Alternative Medicine
and cell-cycle arrest in mouse mesothelioma and melanoma
cell lines without aﬀecting normal cells [14, 15].
Although these ﬁndings demonstrate the anticancer
activity of terpinen-4-ol, the underlying molecular mech-
anisms of the antitumor activity of terpinen-4-ol remain
unclear. In addition, there is no report on the antitumor
eﬀects of terpinen-4-ol against human nonsmall cell lung
cancer cells. Therefore, in this study, the anticancer eﬀects
of terpinen-4-ol were evaluated on two NSCLC cell lines,
namely, A549 and CL1-0 human lung adenocarcinoma
cells. The possible molecular mechanisms responsible for
its anticancer activity were also investigated. Our results
indicated that terpinen-4-ol induced apoptosis through a
mitochondria-mediated pathway in NSCLC cells and that
the apoptosis elicited by terpinen-4-ol was p53 dependent.
Furthermore, treatment of s.c xenografts derived from A549
cells with intratumor injections of terpinen-4-ol signiﬁcantly
inhibited tumor growth compared with the control group.
2.Materialsand Methods
2.1. Cell Culture and Reagents. The A549 human lung
adenocarcinoma and CL1-0 lung adenocarcinoma cell lines
were cultured in Dulbecco s modiﬁed eagle medium supple-
mented with 10% fetal bovine serum (FBS) and 1% antibi-
otic antimycotic. Cultures were maintained in a humidiﬁed
incubatorwith5%CO2 at37◦C.TheA549/p53-shRNAclone
14 cells were established in culture as described by Chang
et al. [16]. Terpinen-4-ol (Sigma-Aldrich, St. Louis, MO)
was 97% pure. A 0.2% stock solution of terpinen-4-ol was
prepared and was subsequently diluted to 0.02%–0.1% in
warm supplemented media [14].
2.2. Cytotoxicity Assay. The cytotoxic eﬀects of terpinen-4-
ol on A549 and CL1-0 cells were measured with the 3-[4,5-
dimethylthiazol-2-yl]-2,5 diphenyltetrazolium (MTT) assay
(Sigma-Aldrich, St. Louis, Mo, USA). The A549 and CL1-0
cells were seeded onto 24-well plates for 24 hours. Various
concentrationsofterpinen-4-ol were added to the cells. After
incubation for 24 hours, the medium was removed, and
200μLo f1× MTT solution was added to each well for 4
hours. The spectrophotometric absorbance of each well was
analyzed by a microplate reader (TECAN) at 540nm. For
analysis of the cytotoxic eﬃciency, we calculated IC50 values
with dose-dependent curves by linear interpolation.
2.3. Western Blot Analysis. Whole-cell protein was lysed
with 2% SDS (10mM EDTA, 50mM Tris base, 10% SDS,
pH 8.0) and boiled at 100◦C for 10 minutes. Protein
concentrations were measured using the BCA protein assay.
Equal amounts of protein were loaded on 10%–15% SDS-
PAGE gels, transferred to PVDF membranes and blocked
with 5% nonfat milk in TBST buﬀer (20mM Tris-HCl,
120mMNaCl, 0.1% Tween 20) for 1 hour. Membranes were
incubatedwithvariousprimary antibodiesagainst CyclinB1,
Cdc2, Cdc25c, Bcl-2, Bax, caspase-3, caspase-9, and PARP
at 4◦C overnight. After washing, the blots were incubated
with HRP-labeled secondary antibodies for 2 hours. The
signals of the blots were then developed using the enhanced
chemiluminescence (ECL) system and analyzed with the
LAS3000 system (Fujiﬁlm, Tokyo, Japan).
2.4. Mitochondria/Cytosol Fractionation. Am i t o c h o n d r i a /
cytosol fractionation kit (Biovision) was used for isolation
of the mitochondrial fraction from the cytosolic fraction
of mammalian cells. Cells were harvested by trypsinization,
washed twice with PBS and resuspended in 500μL of cytosol
extraction buﬀer mix on ice for 10 minutes. Cells were
homogenizedwithaDouncetissuegrinder(Biovision)onice
for 30–50 passes and centrifuged at 3000rpm for 10 minutes
at 4◦C. The supernatants were collected and centrifuged
again at 13000rpm for 30 minutes at 4◦C.
2.5. Cell Cycle Analysis and Sub-G1 Measurement. 3 × 105
cells were plated on 6cm dishes for 24 hours. The cells
were then treated with diﬀerent concentrations of terpinen-
4-ol for diﬀerent periods of time, followed by collecting the
cells by centrifugation. The pellets were mixed with 75%
ethanol at −20◦C overnight. The cells were then centrifuged
and resuspended in 500μL of PI staining solution (2mg/mL
RNase, 1mg/mL PI, 5% Triton X-100) for 1 hour at 37◦C
in the dark. The cells were next analyzed by FACS Calibur
ﬂow cytometry (BD Biosciences). The distribution and
percentages of cells in the sub-G1, G0/G1, S, and G2/M
phases of the cell cycle were further analyzed with WinMDI
software (version 2.9, Joseph Trotter).
2.6. Annexin V Assay. The BioVision annexin V-FITC apop-
tosis detection kit was used for the apoptosis assay (BioVi-
sion). A549and CL1-0 cells were seeded onto 6cmdishes for
24 hours and then exposed to diﬀerent doses of terpinen-4-
olfor 6hours.Cells wereharvested bytrypsinization, washed
twice with PBS, and resuspended in 500μLo fb i n d i n gb u ﬀer.
Cell suspensions were then incubated with 5μL of annexin
V-FITC and 5 μL of propidium iodide (PI) for 10 minutes
at room temperature in the dark. The cells were evaluated
immediately by ﬂow cytometry.
2.7. Mitochondrial Membrane Potential Assay. Mitochon-
dria-speciﬁc cationic dye JC-1 (Invitrogen, Carlsbad, Calf,
USA), which undergoes potential-dependent accumulation
in the mitochondria, was used. When the membrane po-
tential (ΔΨ)i sb e l o w1 2 0m V ,J C - 1i sm o n o m e r i ca n de m i t s
green light (540nm) following excitation with blue light
(490nm). At membrane potentials higher than 120mV, JC-1
monomer aggregates and emits red light (590nm) following
excitation with green light (540nm). For the assay, cells
were seeded onto 96-well plates and treated with various
concentrations of terpinen-4-ol for 24 hours, followed by
staining with 25μMJ C - 1f o r3 0m i n u t e sa t3 7 ◦C. Fluo-
rescence was monitored with a ﬂuorescence plate reader at
wavelengths of 490nm (excitation)/540nm (emission) and
540nm (excitation)/590nm (emission). Changes in the mi-
tochondrial membrane potential were indicated by changes
in the ratio of intensities between the measurements at test
wavelengths of 590nm (red) and 540nm (green).Evidence-Based Complementary and Alternative Medicine 3
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Figure 1: Eﬀects of terpinen-4-ol on viability and morphology of A549 and CL1-0 cells. (a) A549 and CL1-0 cells were seeded at 5 ×
104 cells/well and then treated with the indicated concentrations of terpinen-4-ol for 24 hours following attachment. The cell viability was
determined by the MTT assay. Each point on the graph represents the mean ± SD of triplicate tests.
∗P value <.05 compared with the
untreated control group. (b) The morphology of A549 and CL1-0 cells treated with various concentrations of terpinen-4-ol for 24 hours
were observed by phase-contrast microscopy and photographed (400×).
2.8. In Vivo Antitumor Activity. In total, 1 × 107 A549 cells
were s.c. injected into the right ﬂank of 16 week old female
BALB/c nu/nu mice. Tumor-bearing mice were subdivided
into groups of ﬁve mice. Therapy was initiated 10 days
after tumor inoculation when the mean tumor volume was
50mm3. A stock solution of terpinen-4-ol was made by
dissolving 11μL in 5.5mL PBS with vigorous vortexing.
This 0.2% solution was further diluted in PBS. Tween 80
(ﬁnal concentration0.001%v/v)wasincludedtofacilitate oil
solubility [17]. Mice were intravenously infused daily with
100μL of terpinen-4-ol at the indicated doses (0.06% and
0.1%). Control mice were intravenously infused daily with
100μL of PBS containing 0.001% Tween 80. Tumor volumes
were calculated as length × width × thickness × 0.5 and
expressed in mm3.
2.9. TUNEL Assay. Apoptotic cell death in paraﬃn-em-
bedded tumor tissue sections was examined using the
TdT-FragEL DNA fragmentation detection kit (Calbiochem,
San Diego, Calf, USA) according to the manufacturer’s
instructions. Apoptotic cells were identiﬁed as dark brown
nuclei under a light microscope. The number of apoptotic
cells was counted in ﬁve randomly selected high-power ﬁelds
in a blinded manner.
2.10. Statistical Analysis. Results are expressed as mean ±
SD. Statistical comparisons between two groups of data were
made using an unpaired two-tailed Student’s t-test, and P
values <.05 were considered signiﬁcant.
3.Results
3.1. Cytotoxic Eﬀects of Terpinen-4-ol in A549 and CL1-0
Cells. To determine the cytotoxic eﬀect of terpinen-4-ol on
cell, A549 and CL1-0 cells were treated with 0.02% to 0.1%
terpinen-4-ol for 24 hours, and cell viability was determined
using the MTT assay. As shown in Figure 1(a), the viability
of A549 and CL1-0 cells was markedly reduced by terpinen-
4-ol in a concentration-dependent manner. The results were
expressed as a percentage relative to the control group. At
24 hours, the estimated IC50 values were 0.052% in A549
cells and 0.046% in CL1-0 cells, respectively. In addition, the
morphological changes in terpinen-4-ol-treated cells at 24
hours werealsoexamined using aphasecontrast microscope,
as illustrated in Figure 1(b). At concentrations up to 0.06%,
cellproliferationwasinhibited,butthecellsremained mostly
alive. At concentrations of 0.08% and higher, the compound
induced cell death with marked morphologic changes such
as shrinkage, rounding, and ﬂoating of the cells. These
morphological changes suggested that terpinen-4-ol might
induce apoptotic cell death in human NSCLC cells.4 Evidence-Based Complementary and Alternative Medicine
3.2. Terpinen-4-ol Induces Apoptosis in A549 and CL1-0
Cells. Todeterminewhetherterpinen-4-olcausescellgrowth
inhibition by inducing cell-cycle arrest, A549 and CL1-0
cells were subjected to ﬂow cytometric analysis. Both A549
and CL1-0 cells were exposed to a series of concentrations
of terpinen-4-ol for 24 hours. Figure 2(a) shows that when
exposed to 0.06% terpinen-4-ol for 24 hours, a high number
of cells were arrested in the G2/M phase. Additionally, the
sub-G1 population, which is an indication of cell death,
increased signiﬁcantly in the presence of 0.08% and 0.1%
terpinen-4-ol. To clarify the type of cell death elicited by
terpinen-4-ol, A549 and CL1-0 cells were treated with
various concentrations of terpinen-4-ol for 24 hours and
subjected to ﬂow cytometry analysis after staining with
annexin V-FITC and propidium iodide (PI). As shown in
Figure 2(b), the percentages of early apoptotic death
(annexin V+/PI− and lower right quadrant) and late apop-
totic and necrotic death (annexin V+/PI+ and upper right
quadrant) increased in a dose-dependent manner in A549
cells. The percentage of early apoptotic death in CL1-0 cells
rose at lower doses of terpinen-4-ol but fell slightly at higher
doses, whereas the percentages of late apoptotic and necrotic
death in CL1-0 cells still increased in a dose-dependent
manner. The formerphenomenon seenin CL1-0cellsshould
beattributedtoitshighersensitivitytoterpinen-4-ol,thereby
causing DNA fragmentation to occur earlier. Taken together,
these results suggest that terpinen-4-ol induces apoptosis in
A549 and CL1-0 cells.
3.3. Terpinen-4-ol Induces Caspase-Dependent Cell Death in
A549 and CL1-0 Cells. Apoptosis can be elicited by chem-
otherapeutic agents, and the signal transduction can be gen-
erallydividedintotheintrinsic,mitochondria-mediated, and
extrinsic pathways [18]. These pathways converge at several
downstream points, including caspase-3, and/or caspase-7.
Activated caspase-3 and/or caspase-7 then cleave poly(ADP-
ribose)polymerase (PARP), which eventually leads to apop-
tosis. Thus, to clarify the type of apoptotic pathway induced
by terpinen-4-ol, the cleaved forms of caspase-8, caspase-
9, caspase-3 and PARP were determined by Western blot
analysis. As illustrated in Figure 3(a),t h ec l e a v e d / a c t i v a t e d
forms of caspase-9, caspase-3, and PARP, but not caspase-
8, were induced at higher concentrations of terpinen-4-ol
inA549andCL1-0cells.Activationofcaspase-9andcaspase-
3 by terpinen-4-ol suggests that the mitochondrial pathway
is involved. Therefore, we used various caspase inhibitors to
investigate one step further. As illustrated in Figure 3(b),t h e
speciﬁc caspase 8 inhibitor Z-IETD was completely ineﬀec-
tive at increasing cell viability, thereby excluding the possi-
bility of involvement of the extrinsic pathway in terpinen-
4-ol-induced apoptosis. However, caspase-3 inhibitor Z-
DEVD and the caspase-9 inhibitor Z-LEHD were eﬀective
in rescuing both A549 and CL1-0 cells, indicating that the
intrinsic, mitochondria-mediated apoptotic pathway was the
mechanism executing terpinen-4-ol-induced apoptosis.
3.4. Terpinen-4-ol Induced Loss of Mitochondrial Membrane
Potential and Cytochrome C Release. To conﬁrm that the
intrinsic, mitochondria-mediated apoptotic pathway was
involved, we further measured the mitochondrial membrane
potential (Δψm) in terpinen-4-ol-treated A549 and CL1-0
cells. Loss of mitochondrial membrane potential Δψm is
an indicator of mitochondrial damage during apoptosis.
We used the ﬂuorescent cationic dye JC-1 to examine the
eﬀect of terpinen-4-ol on membrane potential (Δψm). JC-1
is a mitochondria-speciﬁc probe that aggregates in normally
polarized mitochondria and emits red ﬂuorescence. In
apoptotic depolarized cells, where the mitochondrial mem-
brane potential is reduced, JC-1 is diﬀused throughout the
cells and assumes a monomeric form, which emits green
ﬂuorescence.Aconcentration-dependentdecrease inred ﬂu-
orescence was observed in both A549 and CL1-0 cells,
suggesting that terpinen-4-ol treatment led to a reduction in
Δψm (Figure 4(a)). A loss of Δψm can lead to cytochrome c
release from themitochondria into thecytosol,an important
event for apoptosis induction [19]. Thus, the cytosolic
fractions of A549 and CL1-0 cells treated with various doses
of terpinen-4-ol were prepared and analyzed for cytochrome
c release by Western blotting. As shown in Figure 4(b),
cytochrome c expression in the cytosolic fractions was
observed in both A549 and CL1-0 cells treated with higher
concentrations of terpinen-4-ol. Taken together, we veriﬁed
that the mitochondrial pathway was responsible for the
terpinen-4-ol-induced apoptosis.
3.5. Terpinen-4-ol Reduced Bcl-2, Bcl-xl and Iaps Protein
Expression in A549 and CL1-0 Cells. Having shown mito-
chondrial involvement in terpinen-4-ol-induced apoptosis,
we next focused on the Bcl-2 family members, which are
known regulators of cytochrome c release from mitochon-
dria during apoptosis. We examined the protein expression
of a proapoptotic member, Bax, which triggers cytochrome c
release, and an antiapoptotic member, Bcl-2, which inhibits
cytochrome c release [20]. Higher doses of terpinen-4-ol
treatment on A549 and CL1-0 cells for 24 hours resulted
in decreased Bcl-2 protein levels and increased Bax protein
expression (Figure 5).InadditiontotheBcl-2family, theIAP
family proteins also regulate caspase activity, thus aﬀecting
apoptosis [21]. Therefore, the expression of two IAP family
proteins, survivin and XIAP, were determined. As shown in
Figure 5, XIAP and survivin protein expression were reduced
at higher doses of terpinen-4-ol.
3.6. Terpinen-4-ol-Induced Apoptosis Is p53 Dependent. p53
is known to play important roles in apoptosis [22, 23];
therefore, we wanted to determine whether p53 plays an
important role in terpinen-4-ol-induced apoptosis. Our re-
sults showed that tepinen-4-ol increased p53 protein expres-
sion in both A549 and CL1-0 cells. To further clarify the
role of p53 protein, p53 was diminished by shRNA in A549
cells. Althoughcell viability, as determined by the MTT assay
following terpinen-4-ol treatment, was signiﬁcantly lower in
p53-diminished A549 cells compared with wild-type A549
cells (Figure 6(a)), we surprisingly found that terpinen-4-
ol induced mostly necrosis in these cells based on annexin
V ﬂow cytometric analyses (Figure 6(c)). The necrotic cellEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Eﬀects of terpinen-4-ol on cell-cycle distribution in A549 and CL1-0 cells. (a) Cell-cycle analysis of terpinen-4-ol-treated cells.
Cells were treated with the indicated concentrations of terpinen-4-ol for 24 hours, and then, cell-cycle distributions were determined by
propidium iodide (PI) staining and subsequent ﬂow cytometry analysis (Gating for each cell-cycle phase M1: <2N; M2: G0-G1; M3: S;
M4: G2-M). Data are representative of three independent experiments with similar results. (b) Flow cytometry analysis of terpinen-4-ol-
induced apoptosis in A549 and CL1-0 cells. The cells were treated with the indicated concentrations of terpinen-4-ol for 24 hours, followed
by labeling for phosphatidylserine externalization with FITC-annexin-V and cell membrane integrity with PI. The lower right quadrant
(annexin-V+/PI-) represents early apoptosis, while the upper right quadrant (annexin V+/PI+) represents late apoptosis and necrosis. Data
are representative of three independent experiments with similar results.Evidence-Based Complementary and Alternative Medicine 7
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Figure 3: Eﬀects of terpinen-4-ol on caspase activation in A549 and CL1-0 cells. (a) Cells were treated with the indicated concentrations
of terpinen-4-ol for 24 hours. Total cell lysates were prepared, resolved by SDS-PAGE, and immunoblotted with the indicated antibodies to
detect the cleaved formsof caspase-8, caspase-9,caspase-3, and PARP. Data are representative of three independent experiments with similar
results. (b) Cells were treated with terpinen-4-ol and/or the indicated caspase inhibitor for 24 hours, and cell viability was determined using
the MTT assay. Data are mean ± SD of three independent experiments.
deathwas characterized asPI+/annexin V-byﬂowcytometry.
Further analysis demonstrated that terpinen-4-ol failed to
activate caspase 3 and PARP in p53-deﬁcient A549 cells
(Figure 6(b)), which conﬁrmed that necrotic cell death was
occurring. These results suggest that p53 is a prerequisite to
terpinen-4-ol-induced apoptosis.
3.7. Terpinen-4-ol Inhibits A549 Tumor Growth in a S.C.
Tumor Model. The prominent inhibitory eﬀect of terpinen-
4-ol on NSCLC cell proliferation in vitro suggested that it
might suppress tumorgrowthin vivo.To verify this hypothe-
sis,femaleBALB/cnu/numiceweres.c.inoculatedwithA549
cells,followedbytheindicateddosesofterpinen-4-oltherapy
starting on day 10 after tumor inoculation. As shown in
Figure 7(a), terpinen-4-ol dose-dependently reduced tumor
volumein BALB/cn u / n umice. To further conﬁrm the ability
of terpinen-4-ol to elicit apoptosis in vivo, in situ TUNEL
staining was carried out on tissue sections of tumors excised
on day 28 from A549 cell-implanted mice treated with
various doses of terpinen-4-ol. As illustrated in Figure 7(b),
0.1% terpinen-4-ol treatment caused a signiﬁcantly higher
percentageofTUNEL-positiveapoptoticcellscomparedwith
vehicle treatment. These results indicated that terpinen-4-ol
also inhibits the growth of nonsmall lung cancer cells and is
a potent apoptosis-inducing agent in vivo.
4.Discussion
Terpinen-4-ol, a major component of essential oil from
several aromatic plants, is used as an anti-inﬂammatory
and antioxidant agent [9–13]. This compound also exhibits
antiproliferative and antitumor eﬀects in the murine AE17
mesothelioma and B16 melanoma tumor cell lines and hu-
man melanoma M14 WT cells, as well as their drug-resistant
counterparts, M14 adriamicin-resistant cells [14, 15]. Our
results demonstrate for the ﬁrst time that terpinen-4-ol
induces apoptosis in human lung cancer cells in vitro and in8 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Eﬀects of terpinen-4-ol on mitochondrial membrane potential and cytochrome c release in A549 and CL1-0 cells. (a) The cells
were stained with JC-1 ﬂuorescence dye and the change inmitochondrialmembranepotential (ΔΨm) wasexamined by ﬂowcytometry. Data
are representative of three independent experiments with similar results. (b) Cytosolic lysates were prepared and subjected to SDS-PAGE
followed by Western blotting with anticytochrome c antibody. Data are representative of three independent experiments showing similar
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Figure 5: Eﬀects of terpinen-4-ol on the expression of Bcl-2 family proteins and IAPs in A549 and CL1-0 cells. Cells were treated with the
indicated concentrations of terpinen-4-ol for 24 hours. Total cell lysates were prepared, subjected to SDS-PAGE, and immunoblotted with
antibodies to detect Bcl-2, Bcl-xl, Bax, XIAP, and survivin. Data are representative of three independent experiments with similar results.
vivo. Elevation of the Bax/Bcl-2 ratio and a decrease in IAP
family proteins XIAP and survivin were observed following
terpinen-4-ol treatment. Notably, our results also indicated
that terpinen-4-ol-induced apoptosis is p53 dependent.
Apoptosis and necrosis are two typical types of cell
death [18]. Apoptosisis characterized by several biochemical
criteria such as changes in mitochondrial membrane perme-
ability, caspase signaling activation, internucleosomal DNA
cleavage, and the release of intermembrane mitochondrial
proteins [24]. In contrast, necrosis is characterized mostly in
negative terms by the absence of apoptosis parameters, such
as caspase activation [25]. Recently, accumulating evidence
has indicated that the dysregulation of apoptosis contributes
to carcinogenesis [26, 27]. Therefore, it has been suggested
that susceptibility to chemotherapeutic agents is dependent
on the ability of tumor cells to respond to apoptosis. Ter-
pinen-4-ol has been shown to induce caspase-dependent
apoptosis in human melanoma cells. However, terpinen-4-
ol has also been shown to induce necrosis in AE17 murine
mesothelioma and B16 murine melanoma cells [14]. The
diﬀerence in type of cell death elicited by terpinen-4-ol
might be explained by species or cell type diﬀerences. In our
present study, the presence of early apoptotic cells (annexin
V+/PI−), activated forms of caspase-9 and caspase-3, and
PARP cleavageindicated that apoptosis, ratherthan necrosis,
was involved in terpinen-4-ol-induced A549 and CL1-0 cell
death (Figures 2 and 3). Furthermore, the decrease in mito-
chondrial membrane potential and increase in cytochrome
c release into the cytosol conﬁrmed involvement of the
mitochondrialpathwayofapoptosisuponthetreatmentwith
terpinen-4-ol.
Bcl-2 family proteins including proteins that suppress
apoptosis,suchasBcl-2,Bcl-XL,andM cl-1,andpr ot einsthat
promote apoptosis, such as Bad, Bax, and Bid, have been
reported to play a central role in regulating cytochrome c
release from mitochondria [20]. Thus, the balance between
the expression levelsof antiapoptotic and proapoptoticBcl-2
family proteins is critical for the fate ofa cell. Moreover, IAPs
have also been reported to inhibit apoptosis by functioning
as inhibitors of activated eﬀector caspases, such as caspase-3
and caspase-7. IAPs are also able to inhibit the cytochrome
c-induced activation of caspase-9 [21]. Our data revealed
that the protein expression of antiapoptotic Bcl-2, XIAP, and
survivin were reduced and that of proapoptotic Bax was
elevated 24 hours after terpinen-4-ol treatment (Figure 4).
These results revealed the molecular events occurring during
terpinen-4-ol-induced mitochondria-mediated apoptosis.
The p53 tumor-suppressor protein protects against can-
cer by regulating the cellular response to DNA damage,
apoptosis, and oncogene activation [22, 23]. Diminution of
p53 expression by shRNA did not decrease the susceptibility
of A549 cells to terpinen-4-ol-induced cytotoxicity, but a
signiﬁcant reduction in the proportion of apoptosis was
observed in p53-diminished A549 cells. Instead of apoptosis,
necrosis manifested as a result of p53 diminution in A549
cells (Figure 6). This ﬁnding suggests that p53 is essential
to terpinen-4-ol-induced apoptosis in human NSCLC cancer
cellsandthatnecrosis isresponsible forthecytotoxiceﬀectof
terpinen-4-ol in p53-null NSCLC cancer cells. Therefore, the
presence of functional p53 acts as the key factor in switching
necrosis to apoptosis in human NSCLC. This is similar to
a previous study from Lim et al. in which ursodeoxycholic
acid was able to switch oxaliplatin-induced necrosis to
apoptosis by activating the p53-caspase 8 pathway in HepG2
hepatocellular carcinoma [28]. Our results do not exclude
the possibility of a failure to induce apoptosis in cancer cells,
where p53 is mutated and loses its transactivation ability,
because p53 mutations are varied. In other words, terpinen-
4-ol is most eﬀective against cancers with functional p53.
Cell-cycle arrest is a common cause of cell growth in-
hibition [29]. Previous studies have indicated that treat-
ment with terpinen-4-ol induces antiproliferative eﬀects by
causing G1 phase arrest in AE17 murine mesothelioma and
B16 murine melanoma cells [14]. However, in the present
study, we observed that the exposure of A549 and CL1-0
cellstoterpinen-4-olcausedG2/Mphasearrest(Figure 2(a)).
Again, the diﬀerence in type of cell-cycle arrest elicited by
terpinen-4-olmightbeduetospeciesorcell-typediﬀerences.
Cell-cycle progression is controlled by the activation of
a highly conserved family of protein kinases, the cyclin-
dependent kinases (Cdks), and the expression of their cyclin
partners, whereas inhibitors of Cdks, including p21 and p27,
inhibit Cdk activity by binding to Cdk-cyclin complexes
[30, 31]. Assembly of the cyclin B1/Cdc2 protein complex is10 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Eﬀect ofterpinen-4-ol oncell viability, caspase3 activation, andPARP cleavage in A549 and p53-silenced A549 cells. (a)A549 and
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essential for G2-phase progression and G2/Mtransition [32].
In addition Cdc25c phosphatase is a key activator of Cdc2/
cyclinBattheG2/Mtransition. Cdc25cfunctionsby dephos-
phorylating, and thereby activating, Cdc2 [33]. Although it
is not fully understood how DNA damage causes cells to un-
dergo apoptosis at the G2/M checkpoint, our results indicate
that the expression of cyclin B1 and cdc25c decrease when
cells are treated with terpinen-4-ol as compared to the un-
treated control (see in supplementary materials in doi:
10.1155/2012/818261).However, the expression of Cdc2 and
cdk inhibitors p21 and p27 was unaﬀected by terpinen-4-ol
(see in supplementary materials in doi: 10.1155/2012/
818261). One of the important mechanisms through which
p53 can regulate the cell cycle is to induce cdk inhibitor
p21, which can induce G2/M or G1 arrest [34]. Because p21
and p27 protein expression remained unchanged following
terpinen-4-ol treatment, it is plausible that terpinen-4-ol
induces G2/M arrest via a p53 independent mechanism, and
that decreases in the expression of cyclin B1 and Cdc25c
contribute mainly to the G2/M arrest seen in terpinen-4-ol-
treated lung cancer cells.
In conclusion, we demonstrated that caspase-dependent
mitochondrial dysfunction is the mechanism of terpinen-4-
ol-induced apoptosis in nonsmall lung cancer cells. Down-
regulation of Bcl-2, XIAP and survivin suggests that ter-
pinen-4-ol increases the susceptibility of NSCLC cells to
apoptosis induction. Notably, the ability of terpinen-4-ol
toinduceapoptosisinNSCLCcellsisp53-dependent.Finally,
our data also showed that the growth of s.c. xenograft
tumors was remarkably inhibited by intratumoral injection
of terpinen-4-ol, indicating that the agent also has potential
for clinical anticancer activity. However, further work is
needed to develop a suitable formulation for either systemic
administration or convection-enhanced delivery of the com-
pound to patients.
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